Back to Search
Start Over
Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.
- Source :
-
British journal of haematology [Br J Haematol] 2013 Jan; Vol. 160 (2), pp. 207-15. Date of Electronic Publication: 2012 Nov 20. - Publication Year :
- 2013
-
Abstract
- The management of patients with Hodgkin lymphoma (HL) recurring after stem cell transplantation (SCT) and multiply relapsed disease remains challenging. We report on 41 such patients who received bendamustine hydrochloride, a bifunctional mechlorethamine derivative mechanistically unrelated to traditional alkylators, after a median of four prior chemotherapy lines, including SCT in 85% of cases. Bendamustine was given at doses of 90-120 mg/m(2) every 21 or 28 d. At first assessment (2-4 cycles), the overall response rate (ORR) was 78% with 12 (29%) complete (CR) and 20 (49%) partial responses (PR). Upon treatment prolongation to 6-8 courses, 40% of PRs progressed, yielding a final ORR of 58% with 31% of CRs. Eight patients (two CRs, six PRs) were subsequently allotransplanted. Median progression-free and overall survival exceeded 11 and 21 months respectively; complete responders displayed a median disease-free survival above 9 months with a relapse rate of only 30%. Outcomes were independent of disease chemosensitivity, previous transplant and bendamustine dose-intensity. No life-threatening or unexpected adverse events occurred. Within the limits of a retrospective analysis and schedule heterogeneity, these results appear very encouraging and prompt prospective trials to confirm bendamustine as a valuable option in the palliative setting and in cytoreductive strategies before allotransplantation.<br /> (© 2012 Blackwell Publishing Ltd.)
- Subjects :
- Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating adverse effects
Antineoplastic Agents, Alkylating pharmacology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bendamustine Hydrochloride
Cell Cycle Checkpoints drug effects
Combined Modality Therapy
DNA Repair drug effects
Disease-Free Survival
Drug Evaluation
Female
Hematologic Diseases chemically induced
Hematopoietic Stem Cell Transplantation
Hodgkin Disease pathology
Hodgkin Disease radiotherapy
Hodgkin Disease surgery
Humans
Male
Middle Aged
Nitrogen Mustard Compounds adverse effects
Nitrogen Mustard Compounds pharmacology
Off-Label Use
Recurrence
Retrospective Studies
Transplantation, Homologous
Treatment Outcome
Young Adult
Antineoplastic Agents, Alkylating therapeutic use
Hodgkin Disease drug therapy
Nitrogen Mustard Compounds therapeutic use
Salvage Therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2141
- Volume :
- 160
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- British journal of haematology
- Publication Type :
- Academic Journal
- Accession number :
- 23167437
- Full Text :
- https://doi.org/10.1111/bjh.12120